Biogen Alzheimer’s drug success: A big step because almost every dementia trial before it has ended in failure
Biogen’s big success in a new Alzheimer’s drug trial wasn’t just a win for the company. It comes after years of failures with every drug tested for dementia and growing doubts about the drug industry’s narrow focus on amyloid proteins.
What Are Keys 